Journal of South Asian Federation of Obstetrics and Gynaecology

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  16 (2024)
Volume  15 (2023)
Volume  14 (2022)
Volume  13 (2021)
Volume  12 (2020)
Volume  11 (2019)
Volume  10 (2018)
Volume  9 (2017)
Volume  8 (2016)
Volume  7 (2015)
Volume  6 (2014)
Volume  5 (2013)
Volume  4 (2012)
Volume  3 (2011)
Volume  2 (2010)
Volume  1 (2009)
Related articles

VOLUME 16 , ISSUE 2 ( March-April, 2024 ) > List of Articles

REVIEW ARTICLE

Chronic Urticaria in Pregnancy: Physiologic and Hormonal Background for an Immune Skin Disease

Abbas Khalili, Bamdad Sadeghi

Keywords : Autologous serum skin test, Chronic spontaneous urticaria, Cyclosporine, Estrogen, Leptin, Omalizumab, Progesterone, Prolactin, T regulatory

Citation Information : Khalili A, Sadeghi B. Chronic Urticaria in Pregnancy: Physiologic and Hormonal Background for an Immune Skin Disease. J South Asian Feder Obs Gynae 2024; 16 (2):145-149.

DOI: 10.5005/jp-journals-10006-2381

License: CC BY-NC 4.0

Published Online: 23-02-2024

Copyright Statement:  Copyright © 2024; The Author(s).


Abstract

Chronic urticaria (CU) is a cluster of manifestations specified as recurrent pruritic erythematous wheals or angioedema (AE), lasting for more than 6 weeks and complicating 1–2% of the population. Widespread presence of CU is higher in middle-aged women than men (1.3 vs 0.8%). It is proposed that this higher prevalence in women may be linked to female sex hormones, although the precise relationship between sex hormones and immune system function remains to be fully understood. Pregnancy is a condition that impacts CU activity in susceptible individuals. Likewise, CU can have effects on pregnancy, and conversely, pregnancy may alter the presentations of CU. Studies have shown Increased number of mast cells present in skin, and elevated serum levels of autoantibodies such as IgE anti-TPO, IgE anti-dsDNA, and IgE anti-IL-24 in chronic spontaneous urticaria (CSU) patients. The role of autoimmune diseases is crucial in these patients. Based on some evidence, immunologic tolerance is outside of the placenta milieu; and some other inflammatory conditions are alleviated during pregnancy. Chronic urticaria severity, medication before pregnancy, and AE before pregnancy were compromising factors leading to intensified urticaria in pregnancy. Managing CU in pregnant women presents unique challenges. There is little evidence about the safety and efficacy of medications in pregnant women with CU, and the cost/benefit of such treatments should be evaluated. Some studies recommend H1-antihistamines. First-generation H1-antihistamines induce sleepiness and decreased attention by passing blood–brain barrier in CNS. However, second-generation H1-antihistamines have minimal CNS complication with most negligible side effects. Omalizumab, a biological monoclonal antibody against IgE molecules, is recently recommended by the guidelines as one of the therapeutic options in patients with uncontrolled CU. Cyclosporine and systemic corticosteroid are the other reserved options for the treatment of CU in pregnancy. In this review, we focused on the effect of underlying physiologic, hormonal, and immunologic changes during pregnancy over CU. Then assessed the noteworthy changes in the natural course of CU during pregnancy; the therapeutic challenges faced, and the complications associated with of CU and complications of CU during pregnancy.

HTML PDF Share
  1. Sánchez-Borges M, Ansotegui IJ, Baiardini I, et al. The challenges of chronic urticaria part 2: Pharmacological treatment, chronic inducible urticaria, urticaria in special situations. World Allergy Organ J 2021;14(6):100546. DOI: 10.1016/j.waojou.2021.100546.
  2. Zuberbier T, Balke M, Worm M, et al. Epidemiology of urticaria: A representative cross-sectional population survey. Clin Exp Dermatol 2010;35:869–873. DOI: 10.1111/j.1365-2230.2010.03840.x
  3. Sánchez-Borges M, Ansotegui IJ, Baiardini I, et al. The challenges of chronic urticaria part 1: Epidemiology, immunopathogenesis, comorbidities, quality of life, and management. World Allergy Organ J 2021;14(6):100533. DOI: 10.1016/j.waojou.2021.100533
  4. Lapi F, Cassano N, Pegoraro V, et al. Epidemiology of chronic spontaneous urticaria: Results from a nationwide, population-based study in Italy. Br J Dermatol 2016;174(5):996–1004. DOI: 10.1111/bjd.14470.
  5. Staubach P, Eckhardt-Henn A, Dechene M, et al. Quality of life in patients with chronic urticaria is differentially impaired and determined by psychiatric comorbidity. Br J Dermatol 2006;154: 294–298.
  6. Bernstein JA, Bouillet L, Caballero T, et al. Hormonal effects on urticaria and angioedema conditions. J Allergy Clin Immunol Pract 2021;9(6):2209–2219. DOI: 10.1016/j.jaip.2021.04.021.
  7. Kolkhir P, Altrichter S, Asero R, et al. Autoimmune diseases are linked to type IIb autoimmune chronic spontaneous urticaria. Allergy Asthma Immunol Res 2021;13(4):545–559. DOI: 10.4168/aair.2021. 13.4.545.
  8. Konstantinou GN, Asero R, Ferrer M, et al. EAACI taskforce position paper: Evidence for autoimmune urticaria and proposal for defining diagnostic criteria. Allergy 2013;68:27–36. DOI: 10.1111/all.12056.
  9. Gonçalo M, Gimenéz-Arnau A, Al-Ahmad M, et al. The global burden of chronic urticaria for the patient and society. Br J Dermatol 2021;184(2):226–236. DOI: 10.1111/bjd.19561.
  10. Kolkhir P, Muñoz M, Asero R, et al. Autoimmune chronic spontaneous urticaria. J Allergy Clin Immunol 2022;149(6):1819–1831. DOI: 10.1016/j.jaci.2022.04.010.
  11. He L, Yi W, Huang X, et al. Chronic urticaria: Advances in understanding of the disease and clinical management. Clin Rev Allergy Immunol 2021;61(3):424–448. DOI: 10.1007/s12016-021-08886-x.
  12. Bracken SJ, Abraham S, MacLeod AS. Autoimmune theories of chronic spontaneous urticaria. Front Immunol 2019;10:627. DOI: 10.3389/fimmu.2019.00627.
  13. Fricke J, Ávila G, Keller T. Prevalence of chronic urticaria in children and adults across the globe: Systematic review with meta-analysis. Allergy 2020;75(2):423–432. DOI: 10.1111/all.14037.
  14. Gompel A, Fain O, Boccon-Gibod I, et al. Exogenous hormones and hereditary angioedema. Int Immunopharmacol 2020;78:106080. DOI: 10.1016/j.intimp.2019.106080.
  15. Abo S, Smith D, Stadt M, et al. Modelling female physiology from head to Toe: Impact of sex hormones, menstrual cycle, and pregnancy. J Theor Biol 2022;540:111074. DOI: 10.1016/j.jtbi.2022.111074.
  16. Kocatürk E, Al-Ahmad M, Krause K. Effects of pregnancy on chronic urticaria: Results of the PREG-CU UCARE study. Allergy 2021;76(10):3133–3144. DOI: 10.1111/all.14950.
  17. Fuhler GM. The immune system and microbiome in pregnancy. Best Pract Res Clin Gastroenterol 2020;44–45:101671. DOI: 10.1016/j.bpg.2020.101671.
  18. Mor G, Cardenas I, Abrahams V, et al. Inflammation and pregnancy: The role of the immune system at the implantation site. Ann N Y Acad Sci 2011;1221(1):80–87. DOI: 10.1111/j.1749-6632.2010.05938.x.
  19. Ysrraelit MC, Correale J. Impact of sex hormones on immune function and multiple sclerosis development. Immunology 2019;156(1):9–22. DOI: 10.1111/imm.13004.
  20. Barrett JH, Brennan P, Fiddler M, et al. Does rheumatoid arthritis remit during pregnancy and relapse postpartum?: Results from a nationwide study in the United Kingdom performed prospectively from late pregnancy. Arthritis Rheum 1999;42(6):1219–1227. DOI: 10.1002/1529-0131(199906)42:6<1219::AID-ANR19>3.0.CO;2-G.
  21. De Man YA, Dolhain RJ, Van De Geijn FE, et al. Disease activity of rheumatoid arthritis during pregnancy: results from a nationwide prospective study. Arthritis Rheum 2008;59(9):1241–1248. DOI: 10.1002/art.24003.
  22. Chen M, Zeng J, Liu X, et al. Changes in physiology and immune system during pregnancy and coronavirus infection: A review. Eur J Obstet Gynecol Reprod Biol 2020;255:124–128. DOI: 10.1016/j.ejogrb.2020.10.035.
  23. Fan Z, Che H, Yang S, et al. Estrogen and estrogen receptor signaling promotes allergic immune responses: Effects on immune cells, cytokines, and inflammatory factors involved in allergy. Allergol Immunopathol (Madr). 2019;47(5):506–512. DOI:10.1016/j.aller.2019.03.001
  24. Church MK, Kolkhir P, Metz M, et al. The role and relevance of mast cells in urticaria. Immunol Rev 2018;282(1):232–247. DOI: 10.1111/imr.12632.
  25. Kolkhir P, Metz M, Altrichter S, et al. Comorbidity of chronic spontaneous urticaria and autoimmune thyroid diseases: A systematic review. Allergy 2017;72(10):1440–1460. DOI: 10.1111/all.13182. Epub 2017 May 22. PMID: 28407273.
  26. Altrichter S, Frischbutter S, Fok JS, et al. The role of eosinophils in chronic spontaneous urticaria. J Allergy Clin Immunol 2020;145(6):1510–1516. DOI: 10.1016/j.jaci.2020.03.005.
  27. Saini S, Shams M, Bernstein JA, et al. Urticaria and angioedema across the ages. J Allergy Clin Immunol Pract 2020;8(6):1866–1874. DOI:10.1016/j.jaip.2020.03.030.
  28. Yang X, Chen L, Wang S, et al. The correlation between Th17/Treg immune dysregulation and the disease severity in chronic spontaneous urticaria patients. Immun Inflamm Dis 2023;11(7):e920. DOI: 10.1002/iid3.920.
  29. Giménez-Arnau AM, DeMontojoye L, Asero R, et al. The pathogenesis of chronic spontaneous urticaria: The role of infiltrating cells. J Allergy Clin Immunol Pract 2021;9(6):2195–2208. DOI: 10.1016/j.jaip.2021.03.033.
  30. Do TT, Canty EA, Joshi SR. Current and future management of chronic spontaneous urticaria and chronic inducible urticaria. Allergy Asthma Proc 2023;44(1):3–14. DOI: 10.2500/aap.2023.44.220093.
  31. Kasperska-Zajac A, Grzanka A, Damasiewicz-Bodzek A. IL-6 trans signaling in patients with chronic spontaneous urticaria. PLoS One 2015;10(12):e0145751. DOI: 10.1371/journal.pone.0145751.
  32. Sanchez-Margalet V, Martin-Romero C. Human leptin signaling in human peripheral blood mononuclear cells: Activation of the JAK-STAT pathway. Cell Immunol 2001;211(1):30–36. DOI: 10.1006/cimm.2001.1815.
  33. Saini SS, Kaplan AP. Chronic spontaneous urticaria: The devil's itch. J Allergy Clin Immunol Pract 2018;6(4):1097–1106. DOI: 10.1016/j.jaip.2018.04.013.
  34. Jáuregui Presa I, Navajas Rodríguez B, Ramos Bareño B, et al. Chronic urticaria in special populations: Children, pregnancy, lactation and elderly people. Curr Treat Options Allergy 2016;3(4):423–438. DOI: 10.1007/s40521-016-0097-x.
  35. Kocatürk E, Podder I, Zenclussen AC, et al. Urticaria in pregnancy and lactation. Front Allergy 2022;3:892673. DOI: 10.3389/falgy.2022. 892673.
  36. Shelly S, Boaz M, Orbach H. Prolactin and autoimmunity. Autoimmun Rev 2012;11(6–7):A465–A470. DOI:10.1016/j.autrev.2011.11.009.
  37. Li L, Liu R, Peng C. Pharmacogenomics for the efficacy and side effects of antihistamines. Exp Dermatol 2022;31(7):993–1004. DOI: 10.1111/exd.14602.
  38. Yockey LJ, Iwasaki A. Interferons and proinflammatory cytokines in pregnancy and fetal development. Immunity 2018;49(3):397–412. DOI:10.1016/j.immuni.2018.07.017.
  39. Farres MN, El khoderee MM, ELkady HM, et al. Serum Leptin in correlation to clinical severity in patients with chronic urticaria. QJM Int J Med 2021;114(Supplement_1):hcab100. 096. DOI: 10.1093/qjmed/hcab100.096.
  40. Fang L, Egea E, Pereira-Sanandres N, et al. Serum levels of leptin, adiponectin and vitamin D in Colombian adults with chronic urticaria. J Allergy Clin Immunol 2018;141(2):AB54. DOI: 10.1016/j.jaci.2017.12.173
  41. Farres MN, Mahmoud MM, Eissa NM, et al. Assessment of serum leptin in patients with chronic spontaneous urticaria. Egypt J Hosp Med 2022;89(1):6006–6010. DOI: 10.21608/EJHM.2022.266832.
  42. Kamel-Sabry M, Nazmy-Farres M, Abdelnour-Melek N, et al. Prolactin and dehydroepiandrosterone sulfate: Are they related to the severity of chronic urticaria? Arch Med Res 2013;44(1):21–26. DOI: 10.1016/j.arcmed.2012.10.007
  43. Soliman M, Khattab FM, Ebrahim HM, et al. Serum prolactin level in chronic urticaria: Is bromocriptine inducing remission in chronic urticaria? J Dermatol Treat 2018;29(8):826–830. DOI: 10.1080/09546634.2018.1468062.
  44. Gonzalez-Estrada A, Geraci SA. Allergy medications during pregnancy. Am J Med Sci 2016;352(3):326–331. DOI: 10.1016/j.amjms.2016.05.030
  45. Zuberbier T, Abdul Latiff AH. The international EAACI/GA2LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy 2022;77(3):734–766. DOI: doi.org/10.1111/all.15090.
  46. Sánchez-Borges M, Ansotegui IJ, Baiardini I, et al. The challenges of chronic urticaria part 2: Pharmacological treatment, chronic inducible urticaria, urticaria in special situations. World Allergy Organ J 2021;14(6):100546. DOI: 10.1016/j.waojou.2021.100546.
  47. Ye YM, Park JW, Kim SH, et al. Clinical evaluation of the computerized chronic urticaria-specific quality of life questionnaire in Korean patients with chronic urticaria. Clin Exp Dermatol 2012;37(7):722–728. DOI: 10.1111/j.1365-2230.2012.04414.x.
  48. Jáuregui I, Ortiz de Frutos FJ, Ferrer M, et al. Assessment of severity and quality of life in chronic urticaria. J Investig Allergol Clin Immunol 2014;24(2):80–86. PMID: 24834770.
  49. Church DS, Church MK. Pharmacology of antihistamines. World Allergy Organ J 2011;4(3):S22–S27. DOI: 10.1186/1939-4551-4-S3-S2.
  50. Kalpaklioglu F, Baccioglu A. Efficacy and safety of H1-antihistamines: An update. Antiinflamm Antiallergy Agents Med Chem 2012;11(3):230–237. DOI: 10.2174/187152312804142713.
  51. Shawky RM, Seifeldin NS. The relation between antihistamine medication during early pregnancy & birth defects. Egypt J Med Hum Genet 2015;16(4):287–290. DOI: 10.1016/j.ejmhg.2015.04.003.
  52. Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy 2018;73(7):1393–1414. DOI: 10.1111/all.13397.
  53. Matok I, Gorodischer R, Koren G, et al. The safety of H(2)-blockers use during pregnancy. J Clin Pharmacol 2010;50(1):81–87. DOI: 10.1177/0091270009350483. Epub 2009 Sep 29. PMID: 19789371.
  54. Garbis H, Elefant E, Diav-Citrin O, et al. Pregnancy outcome after exposure to ranitidine and other H2-blockers. A collaborative study of the European Network of Teratology Information Services. Reprod Toxicol 2005;19(4):453–458. DOI: 10.1016/j.reprotox.2004.09.002.
  55. Gill SK, O'Brien L, Koren G. The safety of histamine 2 (H2) blockers in pregnancy: a meta- analysis. Dig Dis Sci 2009;54(9):1835–1838. DOI: 10.1007/s10620-008-0587-1.
  56. Agache I, Akdis CA. EAACI Biologicals Guidelines-Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12–17 years old. Allergy 2022;77(1):17–38. DOI: 10.1111/all.15030.
  57. Yuan W, Hu S, Li M, et al. Efficacy and safety of omalizumab in Chinese patients with anti-histamine refractory chronic spontaneous urticaria. Dermatol Ther 2022;35(4):e15303. DOI: 10.1111/dth.15303.
  58. Ramos CL, Namazy J. Monoclonal antibodies (biologics) for allergic rhinitis, asthma, and atopic dermatitis during pregnancy and lactation. Immunol Allergy Clin North Am 2023;43(1):187–197. DOI: 10.1016/j.iac.2022.07.001.
  59. Cho YT, Chan TC, Lee CH, et al. Taiwanese dermatological association consensus for the definition, classification, diagnosis, and management of urticaria: A 2021 update. J Formos Med Assoc 2022;121(7):1191–1203. DOI: 10.1016/j.jfma.2022.02.007.
  60. Namazy JA, Blais L, Andrews EB, et al. Pregnancy outcomes in the omalizumab pregnancy registry and a disease-matched comparator cohort. J Allergy Clin Immunol 2020;145(2):528–536. e1. DOI: 10.1016/j.jaci.2019.05.019.
  61. Namazy J, Cabana MD, Scheuerle AE, et al. The xolair pregnancy registry (EXPECT): The safety of omalizumab use during pregnancy. J Allergy Clin Immunol 2015;135(2):407–412. DOI: 10.1016/j.jaci.2014.08.025.
  62. Liao S-L, Yu M, Zhao Z-T, et al. Case report: Omalizumab for chronic spontaneous urticaria in pregnancy. Front Immunol 2021;12:652973. DOI: 10.3389/fimmu.2021.652973.
  63. Amber T, Tabassum S. Cyclosporin in dermatology: A practical compendium. Dermatol Ther 2020;33(6):e13934. DOI: 10.1111/dth.13934.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.